Create an account

Already have an account?
Technical support
The password is: uppercase and lowercase English letters and numbers, no less than 6 characters


Don’t have an account? Sign up
Forgot password?
  • All
  • Pan Lung Cancer PCR Panel
  • PD-L1 (E1L3N) Assay​
  • BRCA Pro Panel
  • HANDLE Classic NGS Panel
  • Essential NGS Panel
  • Super-ARMS® EGFR Mutation Detection Kit
  • HRD Focus Panel
  • HRD Complete Panel
  • Others

1. Liu Y, Jin B, Shen C, Gao X, Qi X, Ma M, Li H, Hao H, Tang Q, Yang K, Mi Y, Guan J, Feng X, He Z, Li H and Yu W (2023) Somatic and germline aberrations in homologous recombination repair genes in Chinese prostate cancer patients. Front. Oncol. 13:1086517.

2. Kekeeva, T.; Andreeva, Y.; Tanas, A.; Kalinkin, A.; Khokhlova, S.; Tikhomirova, T.; Tyulyandina, A.; Popov, A.; Kuzmenko, M.; Volkonsky, M.; et al. HRD Testing of Ovarian Cancer in Routine Practice: What Are We Dealing With? Int. J. Mol. Sci. 2023, 24, 10497.

3. Feng, Cong et al. Relationship between homologous recombination deficiency and clinical features of breast cancer based on genomic scar score. The Breast, Volume 69, 392 - 400.

4. Lu, S., Pan, H., Wu, L. et al. Efficacy, safety and pharmacokinetics of Unecritinib (TQ-B3101) for patients with ROS1 positive advanced non-small cell lung cancer: a Phase I/II Trial. Sig Transduct Target Ther 8, 249 (2023).

5. Chi, K.N. et al. Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial. Annals of Oncology, Volume 34, Issue 9, 772 - 782.

6. Minghao Wang, Hongtao Xu, Qiang Han & Liang Wang (2023) Significance of YAP1–MAML2 rearrangement and GTF2I mutation in the diagnosis and differential diagnosis of metaplastic thymoma, Annals of Medicine, 55:2.

7. Atsushi OHTSU, Koichi GOTO, Takayuki YOSHINO. Improvement of patient care using cancer genomic profiling: SCRUM-/CIRCULATE-Japan experience. Proceedings of the Japan Academy, Series B, 2023, Volume 99, Issue 8, Pages 241-253.

8. Yang, James Chih-Hsin et al. Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial. Journal of Thoracic Oncology, Volume 18, Issue 12, 1743 - 1755.

9. Fountzilas, E.; Papadopoulou, K.; Chatzikonstantinou, T.; Karakatsoulis, G.; Constantoulakis, P.; Tsantikidi, A.; Tsaousis, G.; Karageorgopoulou, S.; Koumarianou, A.; Mauri, D.; et al. Concordance between Three Homologous Recombination Deficiency (HRD) Assays in Patients with High-Grade Epithelial Ovarian Cancer. Cancers 2023, 15, 5525.

10. Kunimasa, K., Matsumoto, S., Honma, K. et al. Utility of needle biopsy in centrally located lung cancer for genome analysis: a retrospective cohort study. BMC Pulm Med 23, 484 (2023).

11. Jiang, T., Chen, J., Xu, X. et al. On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial. Mol Cancer 21, 4 (2022).

12. Ren, Shengxiang et al. Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial. Journal of Thoracic Oncology, Volume 17, Issue 4, 544 - 557.

13. Xu, Y., Huang, Z., Fang, J., Liu, A., Lu, H., Yu, X., Chen, K., Xu, X., Ma, X., Shi, W., Kim, Y., Hakozaki, T., Addeo, A., Shen, Y., Li, S., & Fan, Y. (2022). Tolerability, safety, and preliminary antitumor activity of fuzuloparib in combination with SHR-1316 in patients with relapsed small cell lung cancer: a multicenter, open-label, two-stage, phase Ib trial. Translational Lung Cancer Research, 11(6), 1069-1078.

14. Liu, X., Zhang, X., Liu, C. et al. Immune and inflammation: related factor alterations as biomarkers for predicting prognosis and responsiveness to PD-1 monoclonal antibodies in cervical cancer. Discov Onc 13, 96 (2022).

15. Wang, Lei-Chi et al. Panoramic Tissue Examination That Integrates 3-Dimensional Pathology Imaging and Gene Mutation: Potential Utility in Non–Small Cell Lung Cancer. Laboratory Investigation, Volume 103, Issue 9, 100195.

16. Gu Y, Zhang S, Liang X, Zhao H, Li X, Lu J. Clinical and Pathological Characteristics and Prognosis of Lung Adenocarcinoma With High-Grade Fetal Features: A Retrospective Analysis. International Journal of Surgical Pathology. 2023;0(0).

17. Pecciarini L, Brunetto E, Grassini G, De Pascali V, Ogliari FR, Talarico A, Marra G, Magliacane G, Redegalli M, Arrigoni G, et al. Gene Fusion Detection in NSCLC Routine Clinical Practice: Targeted-NGS or FISH? Cells. 2023; 12(8):1135.

18. Okimura A, Hirano H, Ito Y, et al. (September 11, 2023) Primary Lung Adenocarcinoma With ALK Gene Rearrangement Mostly Occupied by the Signet-Ring Cell Carcinoma Component: A Case Report. Cureus 15(9): e45068.

19. Ishioka Y, Tanaka H, Makiguchi T, Fujishima S, Nunomura Y, Sakamoto H, Shiratori T, Taima K and Tasaka S: Predictors of efficacy of anamorelin in patients with non‑small cell lung cancer and cachexia: A retrospective study. Oncol Lett 27: 22, 2024

20. Sakamoto T, Matsubara T, Takahama T, et al. Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non–Small Cell Lung Cancer. JAMA Netw Open. 2023;6(12):e2347700.

Subscribe to our newsletter

Subscribe Now